However, no significant differences were observed between K19+ and K19− patients in terms of commonly used tumor markers for HCC, preoperative AFP levels, or the amount of protein induced by vitamin K antagonist‐II (PIVKA‐II; Fig. 3B). This evidence concerns the gene KRT19 and hepatocellular carcinoma.